Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 759

1.

From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care.

Curigliano G, Cardoso F, Costa A, Galimberti V, Goldhirsch A, Pelicci PG, Veronesi P, Viale G, Orecchia R.

Breast. 2017 Feb;31:241-243. doi: 10.1016/j.breast.2016.11.013. No abstract available.

PMID:
27876474
2.

Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?

Criscitiello C, Curigliano G, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M.

Eur J Surg Oncol. 2016 Dec;42(12):1780-1786. doi: 10.1016/j.ejso.2016.10.011. Review.

PMID:
27825710
3.

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.

Johansson H, Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA; the TEXT principal investigators..

Breast Cancer Res. 2016 Nov 8;18(1):110.

4.

Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study.

Toesca A, Peradze N, Manconi A, Galimberti V, Intra M, Colleoni M, Bonanni B, Curigliano G, Rietjens M, Viale G, Sacchini V, Veronesi P.

Breast. 2017 Feb;31:51-56. doi: 10.1016/j.breast.2016.10.009.

PMID:
27810700
5.

Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment.

Orlando L, Viale G, Bria E, Lutrino ES, Sperduti I, Carbognin L, Schiavone P, Quaranta A, Fedele P, Caliolo C, Calvani N, Criscuolo M, Cinieri S.

Breast. 2016 Dec;30:151-155. doi: 10.1016/j.breast.2016.09.015.

PMID:
27750105
6.

ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer.

Grandi A, Santi A, Campagnoli S, Parri M, De Camilli E, Song C, Jin B, Lacombe A, Castori-Eppenberger S, Sarmientos P, Grandi G, Viale G, Terracciano L, Chiarugi P, Pileri P, Grifantini R.

Oncotarget. 2016 Sep 27;7(39):63596-63610. doi: 10.18632/oncotarget.11550.

7.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators..

N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.

8.

Clinical and pathological assessment of high-risk ductal and lobular breast lesions: What surgeons must know.

Mastropasqua MG, Viale G.

Eur J Surg Oncol. 2016 Aug 5. pii: S0748-7983(16)30681-3. doi: 10.1016/j.ejso.2016.07.011. [Epub ahead of print] Review.

PMID:
27544280
9.

HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study.

Kim WH, Gomez-Izquierdo L, Vilardell F, Chu KM, Soucy G, Dos Santos LV, Monges G, Viale G, Brito MJ, Osborne S, Noé J, Du X.

Appl Immunohistochem Mol Morphol. 2016 Aug 3. [Epub ahead of print]

PMID:
27490762
10.

Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.

Viale G, Paterson J, Bloch M, Csathy G, Allen D, Dell'Orto P, Kjærsgaard G, Levy YY, Jørgensen JT.

Pathol Res Pract. 2016 Aug;212(8):735-42. doi: 10.1016/j.prp.2016.06.002.

11.

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.

Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancello G, Munzone E, Gelber RD, Regan MM, Colleoni M.

Breast Cancer Res Treat. 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3.

PMID:
27372069
12.

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.

Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, O'Toole SA, Viale G, Van de Vijver K, de Wind R, von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R.

Mod Pathol. 2016 Oct;29(10):1155-64. doi: 10.1038/modpathol.2016.109.

PMID:
27363491
13.

An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.

Dama E, Melocchi V, Dezi F, Pirroni S, Carletti RM, Brambilla D, Bertalot G, Casiraghi M, Maisonneuve P, Barberis M, Viale G, Vecchi M, Spaggiari L, Bianchi F, Di Fiore PP.

Clin Cancer Res. 2017 Jan 1;23(1):62-72. doi: 10.1158/1078-0432.CCR-15-3005.

PMID:
27358486
14.

HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence.

Criscitiello C, Bagnardi V, Viale G, Disalvatore D, Rotmensz N, Esposito A, Goldhirsch A, Curigliano G.

Anticancer Res. 2016 Jul;36(7):3537-40.

PMID:
27354620
15.

FAT1: a potential target for monoclonal antibody therapy in colon cancer.

Pileri P, Campagnoli S, Grandi A, Parri M, De Camilli E, Song C, Ganfini L, Lacombe A, Naldi I, Sarmientos P, Cinti C, Jin B, Grandi G, Viale G, Terracciano L, Grifantini R.

Br J Cancer. 2016 Jun 28;115(1):40-51. doi: 10.1038/bjc.2016.145.

PMID:
27328312
16.

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

Colleoni M, Gray KP, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi EA, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch A.

J Clin Oncol. 2016 Oct 1;34(28):3400-8. doi: 10.1200/JCO.2015.65.6595.

PMID:
27325862
17.

Impact of autoimmune diseases on outcome of patients with early breast cancer.

Criscitiello C, Bagnardi V, Esposito A, Gelao L, Santillo B, Viale G, Rotmensz N, Goldhirsch A, Curigliano G.

Oncotarget. 2016 Aug 9;7(32):51184-51192. doi: 10.18632/oncotarget.9966.

18.

RAB2A controls MT1-MMP endocytic and E-cadherin polarized Golgi trafficking to promote invasive breast cancer programs.

Kajiho H, Kajiho Y, Frittoli E, Confalonieri S, Bertalot G, Viale G, Di Fiore PP, Oldani A, Garre M, Beznoussenko GV, Palamidessi A, Vecchi M, Chavrier P, Perez F, Scita G.

EMBO Rep. 2016 Jul;17(7):1061-80. doi: 10.15252/embr.201642032.

PMID:
27255086
19.

Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer.

Dama E, Tillhon M, Bertalot G, de Santis F, Troglio F, Pessina S, Passaro A, Pece S, de Marinis F, Dell'Orto P, Viale G, Spaggiari L, Di Fiore PP, Bianchi F, Barberis M, Vecchi M.

Oncotarget. 2016 Jun 14;7(24):37160-37176. doi: 10.18632/oncotarget.9471.

20.

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.

Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart MJ, Dowsett M, Michiels S, Leyland-Jones B.

JAMA Oncol. 2016 Aug 1;2(8):1040-7. doi: 10.1001/jamaoncol.2016.0339.

PMID:
27100299
Items per page

Supplemental Content

Loading ...
Support Center